The mechanism of action of lenalidomide in MM is not well understood but may relate to tumor necrosis factor (TNF)-alpha inhibition, downregulation of proinflammatory cytokines, direct cytotoxic effects on myeloma cells, and antiangiogenic activity. Here, TNF is linked to Miyoshi myopathy.